Neurofibromatosis type 1 and associated malignancies

  • Kaleb YohayEmail author


Neurofibromatosis type 1 (NF1) is a common autosomal dominant neurocutaneous disorder with a predisposition to the development of benign and malignant tumors. Mutations in the NF1 gene result in loss of function of neurofibromin, a guanosine triphosphatase-activating protein that helps maintain the proto-oncogene Ras in its inactive form. Loss of neurofibromin results in increased proliferation and tumorigenesis. As a result, people with NF1 are at increased risk for the development of nervous and non-nervous system malignancies. Malignancy is a major source of morbidity and mortality in NF1. The natural history of NF1-associated malignancies is often different than that of their sporadic counterparts and, as such, management strategies need to be adjusted accordingly.


Pilocytic Astrocytoma Malignant Peripheral Nerve Sheath Tumor Optic Pathway Optic Pathway Glioma Juvenile Myelomonocytic Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References and Recommended Reading

  1. 1.
    Rasmussen SA, Friedman JM: NF1 gene and neurofibromatosis 1. Am J Epidemiol 2000, 151:33–40.PubMedGoogle Scholar
  2. 2.
    Riccardi VM, Lewis RA: Penetrance of von Recklinghausen neurofibromatosis: a distinction between predecessors and descendants. Am J Hum Genet 1988, 42:284–289.PubMedGoogle Scholar
  3. 3.
    Littler M, Morton NE: Segregation analysis of peripheral neurofibromatosis (NF1). J Med Genet 1990, 27:307–310.PubMedCrossRefGoogle Scholar
  4. 4.
    Cnossen MH, van der Est MN, Breuning MH, et al.: Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 1? Hum Mutat 1997, 9:458–464.PubMedCrossRefGoogle Scholar
  5. 5.
    Basu TN, Gutmann DH, Fletcher JA, et al.: Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992, 356:713–715.PubMedCrossRefGoogle Scholar
  6. 6.
    Balgobind BV, Van Vlierberghe P, van den Ouweland AM, et al.: Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 2008, 111:4322–4328.PubMedCrossRefGoogle Scholar
  7. 7.
    Teschendorff AE, Journee M, Absil PA, et al.: Elucidating the altered transcriptional programs in breast cancer using independent component analysis. PLoS Comput Biol 2007, 3:e161.PubMedCrossRefGoogle Scholar
  8. 8.
    Upadhyaya M, Kluwe L, Spurlock G, et al.: Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat 2008, 29:74–82.PubMedCrossRefGoogle Scholar
  9. 9.
    Ding L, Getz G, Wheeler DA, et al.: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069–1075.PubMedCrossRefGoogle Scholar
  10. 10.
    Mrozek K: Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 2008, 35:365–377.PubMedCrossRefGoogle Scholar
  11. 11.
    Sangha N, Wu R, Kuick R, et al.: Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia 2008, 10:1362–1372, following 1372.PubMedGoogle Scholar
  12. 12.
    Harris GJ, Plotkin SR, Maccollin M, et al.: Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 2008, 62:1314–1319; discussion 1319–1320.PubMedCrossRefGoogle Scholar
  13. 13.
    Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061–1068.CrossRefGoogle Scholar
  14. 14.
    Zoller M, Rembeck B, Akesson HO, Angervall L: Life expectancy, mortality and prognostic factors in neuro-fibromatosis type 1. A twelve-year follow-up of an epidemiological study in Goteborg, Sweden. Acta Derm Venereol 1995, 75:136–140.PubMedGoogle Scholar
  15. 15.
    Zoller ME, Rembeck B, Oden A, et al.: Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997, 79:2125–2131.PubMedCrossRefGoogle Scholar
  16. 16.
    Walker L, Thompson D, Easton D, et al.: A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006, 95:233–238.PubMedCrossRefGoogle Scholar
  17. 17.
    Rasmussen SA, Yang Q, Friedman JM: Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001, 68:1110–1118.PubMedCrossRefGoogle Scholar
  18. 18.
    Huson SM, Harper PS, Compston DA: Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988, 111(Pt 6):1355–1381.PubMedCrossRefGoogle Scholar
  19. 19.
    McKeever K, Shepherd CW, Crawford H, Morrison PJ: An epidemiological, clinical and genetic survey of neurofibromatosis type 1 in children under sixteen years of age. Ulster Med J 2008, 77:160–163.PubMedGoogle Scholar
  20. 20.
    Rodriguez FJ, Perry A, Gutmann DH, et al.: Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 2008, 67:240–249.PubMedCrossRefGoogle Scholar
  21. 21.
    Guillamo JS, Creange A, Kalifa C, et al.: Prognostic factors of CNS tumours in neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 2003, 126(Pt 1):152–160.PubMedGoogle Scholar
  22. 22.
    Gutmann DH, Rasmussen SA, Wolkenstein P, et al.: Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 2002, 59:759–761.PubMedGoogle Scholar
  23. 23.
    Listernick R, Charrow J, Greenwald M, Mets M: Natural history of optic pathway tumors in children with neuro-fibromatosis type 1: a longitudinal study. J Pediatr 1994, 125:63–66.PubMedCrossRefGoogle Scholar
  24. 24.
    Listernick R, Darling C, Greenwald M, et al.: Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 1995, 127:718–722.PubMedCrossRefGoogle Scholar
  25. 25.
    Lewis RA, Gerson LP, Axelson KA, et al.: von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata. Ophthalmology 1984, 91:929–935.PubMedGoogle Scholar
  26. 26.
    Balcer LJ, Liu GT, Heller G, et al.: Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol 2001, 131:442–445.PubMedCrossRefGoogle Scholar
  27. 27.
    Listernick R, Ferner RE, Piersall L, et al.: Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology 2004, 63:1944–1946.PubMedGoogle Scholar
  28. 28.
    Thiagalingam S, Flaherty M, Billson F, North K: Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 2004, 111:568–577.PubMedCrossRefGoogle Scholar
  29. 29.
    King A, Listernick R, Charrow J, et al.: Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A 2003, 122A:95–99.PubMedCrossRefGoogle Scholar
  30. 30.
    Gottschalk S, Tavakolian R, Buske A, et al.: Spontaneous remission of chiasmatic/hypothalamic masses in neuro-fibromatosis type 1: report of two cases. Neuroradiology 1999, 41:199–201.PubMedCrossRefGoogle Scholar
  31. 31.
    Parsa CF, Hoyt CS, Lesser RL, et al.: Spontaneous regression of optic gliomas: thirteen cases documented by serial neuroimaging. Arch Ophthalmol 2001, 119:516–529.PubMedGoogle Scholar
  32. 32.
    Mahoney DH Jr, Cohen ME, Friedman HS, et al.: Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro Oncol 2000, 2:213–220.PubMedCrossRefGoogle Scholar
  33. 33.
    Packer RJ, Ater J, Allen J, et al.: Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997, 86:747–754.PubMedCrossRefGoogle Scholar
  34. 34.
    Listernick R, Ferner RE, Liu GT, Gutmann DH: Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007, 61:189–198.PubMedCrossRefGoogle Scholar
  35. 35.
    Sharif S, Ferner R, Birch JM, et al.: Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006, 24:2570–2575.PubMedCrossRefGoogle Scholar
  36. 36.
    Grill J, Couanet D, Cappelli C, et al.: Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol 1999, 45:393–396.PubMedCrossRefGoogle Scholar
  37. 37.
    Molloy PT, Bilaniuk LT, Vaughan SN, et al.: Brainstem tumors in patients with neurofibromatosis type 1: a distinct clinical entity. Neurology 1995, 45:1897–1902.PubMedGoogle Scholar
  38. 38.
    Ullrich NJ, Raja AI, Irons MB, et al.: Brainstem lesions in neurofibromatosis type 1. Neurosurgery 2007, 61:762–766; discussion 766–767.PubMedCrossRefGoogle Scholar
  39. 39.
    Bilaniuk LT, Molloy PT, Zimmerman RA, et al.: Neuro-fibromatosis type 1: brain stem tumours. Neuroradiology 1997, 39:642–653.PubMedCrossRefGoogle Scholar
  40. 40.
    Pollack IF, Shultz B, Mulvihill JJ: The management of brainstem gliomas in patients with neurofibromatosis 1. Neurology 1996, 46:1652–1660.PubMedGoogle Scholar
  41. 41.
    Ducatman BS, Scheithauer BW, Piepgras DG, et al.: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986, 57:2006–2021.PubMedCrossRefGoogle Scholar
  42. 42.
    Evans DG, Baser ME, McGaughran J, et al.: Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002, 39:311–314.PubMedCrossRefGoogle Scholar
  43. 43.
    McCaughan JA, Holloway SM, Davidson R, Lam WW: Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1. J Med Genet 2007, 44:463–466.PubMedCrossRefGoogle Scholar
  44. 44.
    De Raedt T, Brems H, Wolkenstein P, et al.: Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 2003, 72:1288–1292.PubMedCrossRefGoogle Scholar
  45. 45.
    King AA, Debaun MR, Riccardi VM, Gutmann DH: Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet 2000, 93:388–392.PubMedCrossRefGoogle Scholar
  46. 46.
    Tucker T, Wolkenstein P, Revuz J, et al.: Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 2005, 65:205–211.PubMedCrossRefGoogle Scholar
  47. 47.
    Mautner VF, Friedrich RE, von Deimling A, et al.: Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma. Neuroradiology 2003, 45:618–625.PubMedCrossRefGoogle Scholar
  48. 48.
    Bhargava R, Parham DM, Lasater OE, et al.: MR imaging differentiation of benign and malignant peripheral nerve sheath tumors: use of the target sign. Pediatr Radiol 1997, 27:124–129.PubMedCrossRefGoogle Scholar
  49. 49.
    Bredella MA, Torriani M, Hornicek F, et al.: Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol 2007, 189:928–935.PubMedCrossRefGoogle Scholar
  50. 50.
    Ferner RE, Lucas JD, O’Doherty MJ, et al.: Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 2000, 68:353–357.PubMedCrossRefGoogle Scholar
  51. 51.
    Ferner RE, Gutmann DH: International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002, 62:1573–1577.PubMedGoogle Scholar
  52. 52.
    Grobmyer SR, Reith JD, Shahlaee A, et al.: Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol 2008, 97:340–349.PubMedCrossRefGoogle Scholar
  53. 53.
    Evans DG, Birch JM, Ramsden RT, et al.: Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 2006, 43:289–294.PubMedCrossRefGoogle Scholar
  54. 54.
    Creange A, Zeller J, Rostaing-Rigattieri S, et al.: Neurological complications of neurofibromatosis type 1 in adulthood. Brain 1999, 122(Pt 3):473–481.PubMedCrossRefGoogle Scholar
  55. 55.
    Hagel C, Zils U, Peiper M, et al.: Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol 2007, 82:187–192.PubMedCrossRefGoogle Scholar
  56. 56.
    Cashen DV, Parisien RC, Raskin K, et al.: Survival data for patients with malignant schwannoma. Clin Orthop Relat Res 2004, (426):69–73.PubMedCrossRefGoogle Scholar
  57. 57.
    Anghileri M, Miceli R, Fiore M, et al.: Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006, 107:1065–1074.PubMedCrossRefGoogle Scholar
  58. 58.
    Side L, Taylor B, Cayouette M, et al.: Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997, 336:1713–1720.PubMedCrossRefGoogle Scholar
  59. 59.
    Stiller CA, Chessells JM, Fitchett M: Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 1994, 70:969–972.PubMedGoogle Scholar
  60. 60.
    Zvulunov A, Barak Y, Metzker A: Juvenile xanthogranuloma, neurofibromatosis, and juvenile chronic myelogenous leukemia. World statistical analysis. Arch Dermatol 1995, 131:904–908.PubMedCrossRefGoogle Scholar
  61. 61.
    Walther MM, Herring J, Enquist E, et al.: von Recklinghausen’s disease and pheochromocytomas. J Urol 1999, 162:1582–1586.PubMedCrossRefGoogle Scholar
  62. 62.
    Sharif S, Moran A, Huson SM, et al.: Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 2007, 44:481–484.PubMedCrossRefGoogle Scholar
  63. 63.
    Guillot B, Dalac S, Delaunay M, et al.: Cutaneous malignant melanoma and neurofibromatosis type 1. Melanoma Res 2004, 14:159–163.PubMedCrossRefGoogle Scholar
  64. 64.
    Hottinger AF, Khakoo Y: Update on the management of familial central nervous system tumor syndromes. Curr Neurol Neurosci Rep 2007, 7:200–207.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Division of Child Neurology, Department of Pediatrics, Weill Cornell Medical CollegeNew York-Presbyterian HospitalNew YorkUSA

Personalised recommendations